Stem Cell Therapeutics Corp. Announces Top-Line Results for the Modified REGENESIS Phase IIb Stroke Trial
Stem Cell Therapeutics Corp. (”SCT” or the “Company”) (TSX VENTURE: SSS) announced today the top-line results for the modified REGENESIS-Phase IIb stroke trial. The modified REGENESIS- Phase IIb trial, a placebo controlled, double blinded, 3:1 randomized clinical study, enrolled 96 patients with acute ischemic stroke between August 2009 and January 24, 2010. SCT reports that the top-line primary …
[Read the full article here]Related News:
Stem Cell Therapeutics Corp. Announces Completion of Enrollment in Key Modified REGENESIS Phase IIb Stroke Trial
Stem Cell Therapeutics Corp. Announces The Date For The Release Of Top-Line Results In The Modified REGENESIS Phase …
Stem Cell Therapeutics Corp. Provides Update on Modified REGENESIS Phase IIb Stroke Trial